Kalaris Therapeutics (KLRS)Director bought ~$5M

~$5M

Approx. value · 480K sh @ $10.42

1.98M

Holds after · shares reported

Traded

Dec 18, 2025

Filed

Feb 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 28, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 28, 2025, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Matthew Gall as Chief Financial Officer and Treasurer of the Company, effective as of November 3, 2025 (the “Effective Date”).”
2. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
3. Dec 17, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
4. Dec 18, 2025 · this disclosureInsider · First insider buy since Jun 2023Director purchased ~$5M of KLRS shares in the open market

What came next

1. Mar 17, 2026Company filing · Form 8-K · ResultsReported its results
2. Mar 20, 2026InsiderOfficer sold ~$13K of KLRS shares in the open market
3. Apr 8, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the “Company”) of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the “Separation Date”).”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Kalaris Therapeutics

OQRO holds no insider, Congress, fund or contract record for Kalaris Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KLRS page.

Other recent filings by Srinivas Akkaraju, Director

• SEC Form 4 at Kalaris Therapeutics (KLRS)May 22, 2026
• SEC Form 4 at Mineralys Therapeutics (MLYS)Sep 9, 2025
• SEC Form 4 at Alumis (ALMS)May 6, 2025
• SEC Form 4 at Alumis (ALMS)May 6, 2025
• SEC Form 4 at Alumis (ALMS)May 6, 2025

The full history of Srinivas Akkaraju, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Kalaris Therapeutics

• SEC Form 4May 22, 2026
• SEC Form 4Mar 23, 2026
• SEC Form 4Mar 27, 2025
• SEC Form 4Feb 24, 2025
• SEC Form 4Feb 24, 2025
• SEC Form 4Feb 24, 2025

Everything OQRO holds on this company is on its KLRS page.